Glucagon-Like Peptide-1 receptor agonists

Phase 1Small molecule

Glucagon-Like Peptide-1 receptor agonists is one of 120 small molecule programs targeting Diabetic Nephropathy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

119

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic NephropathyActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Osteoarthritis (OA) of the KneeActive, not recruiting

OverweightCompleted

Diabetic NephropathyPreclinical

Active, not recruiting

Chronic Kidney DiseasePreclinical

Active, not recruiting

Osteoarthritis (OA) of the KneePhase 1

Active, not recruiting

OverweightPreclinical

Completed

Competition

Competitive Landscape

172 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

17 2

Uloric

Takeda

Preclinical

2 3

Sovaldi

Gilead

Preclinical

1 4

Glucotrol

Pfizer

Preclinical

1 5

Vemlidy

Gilead

Preclinical

1 6

Lorelco

Sanofi

Preclinical

1 7

Activase

Flomax

PROCRIT

1 10

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Active, not recruiting

Osteoarthritis (OA) of the Knee

NCT06807970

Q4 2028

Recruiting

Diabetic Nephropathy

NCT07444203

Clinical

Trials by Indication[1]

Ultrasound1 trial

GLP_1 RA Ultrasound Study

Enrolling by invitation·—··NCT06581120·100 enrolled

Diabetic Nephropathy1 trial

Transformative Research in Diabetic Nephropathy 2.0

Recruiting·UUniversity of Pennsylvania··NCT07444203·200 enrolled

Chronic Kidney Disease1 trial

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

Completed· Bayer logo

Bayer··NCT05526157·50,000 enrolled

Overweight1 trial

Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF

Completed·SShanghai Chest Hospital·N/A·NCT06660134·174 enrolled

Osteoarthritis (OA) of the Knee1 trial

Novel Perioperative Optimization of Obese Osteoarthritic Patients Pending Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist (NPO-OOPS-TKR)

Active, not recruiting·TThe University of Hong Kong·Phase 1·NCT06807970·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Glucagon-Like Peptide-1 receptor agonists. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glucagon-Like Peptide-1 receptor agonists compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glucagon-Like Peptide-1 receptor agonists. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Bayer

Glucagon-Like Peptide-1 receptor agonists

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Trials by Indication[1]

Ultrasound1 trial

Diabetic Nephropathy1 trial

Chronic Kidney Disease1 trial

Overweight1 trial

Osteoarthritis (OA) of the Knee1 trial

References

Drug Info

Quick Facts

Related News